- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Gaithersburg Today
By the People, for the People
Emergent BioSolutions swings to $52.6M 2025 profit
Despite a 29% revenue drop to $742.9M, Emergent delivered $205M in adjusted EBITDA, swung to $52.6M net income and repaid $100M of term loan debt.
Published on Feb. 26, 2026
Got story updates? Submit your updates here. ›
Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year ended December 31, 2025. The company's 2025 results demonstrate significant progress executing its multi-year turnaround strategy, delivering improved operating margins, strong adjusted EBITDA of $205 million, increased cash flow and lower leverage.
Why it matters
Emergent's performance highlights the company's ability to navigate challenges, maintain market leadership, and invest in future growth while improving its balance sheet and returning capital to shareholders. The results demonstrate Emergent's commitment to its mission of protecting and saving lives through critical medical countermeasures and naloxone products.
The details
In 2025, Emergent secured key contract awards, exercised options and received product orders across its Medical Countermeasures business totaling more than $450 million in revenue. The company also maintained its market leadership position in the naloxone business, generating more than $226 million in revenue. Emergent completed the sale of its Baltimore-Bayview facility for $36.5 million and gained exclusive commercial rights to KLOXXADO® (naloxone HCI) Nasal Spray in the U.S. and Canada.
- In 2025, the Board of Directors authorized the repurchase of up to $50.0 million of the Company's common stock and repurchased $24.8 million of shares during the year.
- A new plan was authorized by the Board of Directors for up to $50.0 million in repurchases from February 25, 2026 through March 31, 2027.
- Emergent made a voluntary debt payment of $100.0 million toward its Term Loan Principal in 2025.
The players
Emergent BioSolutions Inc.
An American biopharmaceutical company that develops and manufactures specialty pharmaceuticals and medical devices for the prevention and treatment of infectious diseases.
Joe Papa
President and CEO of Emergent BioSolutions.
What they’re saying
“Emergent's 2025 results demonstrate significant progress executing our multi-year turnaround strategy, delivering improved operating margins, strong adjusted EBITDA of $205 million, increased cash flow and lower leverage.”
— Joe Papa, President and CEO of Emergent BioSolutions (Emergent BioSolutions)
The takeaway
Emergent's performance in 2025 showcases its ability to adapt, innovate and deliver value despite industry challenges. The company's focus on operational efficiency, debt reduction and strategic investments positions it for continued success in protecting and saving lives through its critical medical countermeasures and naloxone products.
